Cobalamin C Disease: Causes, Symptoms, and Treatment

Cobalamin C disease is a rare inherited disorder caused by mutations in the MMACHC gene, which cripples the body’s ability to process vitamin B12 into the forms cells actually need. Without those active forms of B12, two critical metabolic pathways stall at once, causing a toxic buildup of methylmalonic acid and homocysteine in the blood. The condition can affect virtually every organ system and ranges from a devastating illness in newborns to a subtler, later-emerging syndrome in adolescents and adults. Treatment centers on high-dose injections of a special form of B12, but even with early therapy, many patients face lasting developmental and visual challenges.

What Goes Wrong at the Cellular Level

Your body takes in vitamin B12 from food, but that dietary B12 is not immediately useful. Inside cells, a protein called MMACHC processes raw B12 into two active coenzymes: adenosylcobalamin and methylcobalamin. Adenosylcobalamin helps an enzyme break down certain fats and proteins, while methylcobalamin helps a different enzyme convert the amino acid homocysteine into methionine, which cells need for growth and DNA regulation.¹ When MMACHC is broken, neither coenzyme gets made properly. The result is a dual biochemical problem: methylmalonic acid accumulates because it cannot be processed, and homocysteine accumulates because it cannot be converted to methionine. At the same time, methionine levels drop too low. That combination of too much of two toxic metabolites and too little of an essential amino acid is what drives the wide-ranging damage seen in cobalamin C disease.

The Genetic Cause and Why Severity Varies

Cobalamin C disease follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the MMACHC gene from each parent to develop the condition. Carriers, who have one working copy and one broken copy, are typically healthy and unaware they carry the mutation.

More than 80 different mutations in MMACHC have been cataloged, and specific mutations correlate with how severe the disease becomes. The most commonly reported mutation linked to early-onset disease tends to eliminate or severely truncate the MMACHC protein. By contrast, a different common mutation (known as c.394C>T) is associated with late-onset disease; cell lines carrying that mutation produce higher levels of the gene’s messenger RNA than cell lines carrying the early-onset mutations, which may explain why enough residual protein function remains to delay symptoms for years or even decades.²

This genotype-phenotype relationship is not absolute. Two people carrying the same pair of mutations can still differ in the age when symptoms appear and how severely they are affected. Environmental factors, dietary B12 intake, and possibly the behavior of other genes involved in B12 trafficking all seem to modify the picture.

Early-Onset Symptoms in Infants

The classic and most severe form of cobalamin C disease shows up in the first weeks or months of life. A study of eleven early-onset patients found that every single one had feeding difficulties and low muscle tone at presentation, and nearly all had blood abnormalities and failure to thrive. Microcephaly was present in the majority. Over half had seizures, and roughly half had hydrocephalus. Some developed cardiomyopathy or hemolytic uremic syndrome, a dangerous condition affecting the blood and kidneys.³

The picture in early-onset cases is often alarming: a baby who was born looking well may rapidly develop lethargy or coma, refuse feeds, and show abnormal blood counts within the first weeks of life. Doctors who are not thinking about metabolic disease sometimes mistake the presentation for sepsis or a primary blood disorder, which can delay the correct diagnosis.

Late-Onset Disease in Adolescents and Adults

A less recognized form of the disease appears much later, sometimes not until the twenties or thirties. In a study of adolescent and adult patients, the average age at first symptoms was 26 years, and the dominant features were neurological problems and blood clots rather than the feeding difficulties and organ failure seen in babies.⁴ Late-onset patients may be entirely asymptomatic for years before developing neuropsychiatric symptoms, thromboembolic events, or kidney disease.⁵

The neurological symptoms in these adults can mimic other conditions. Cognitive decline, psychiatric changes, and spinal cord degeneration resembling subacute combined degeneration (the type of spinal cord damage classically seen in severe B12 deficiency) have all been documented.⁶ Because ordinary B12 deficiency from diet or absorption problems is far more common, physicians may try standard B12 supplementation and assume the case is solved, missing the underlying genetic defect. Late-onset cobalamin C disease should be suspected when a patient has both elevated methylmalonic acid and elevated homocysteine that do not fully correct with standard B12 replacement, especially if blood clots or unexplained kidney disease are part of the picture.

Eye Complications

Vision problems are one of the most stubborn features of cobalamin C disease, particularly in the early-onset form. The retina appears to be uniquely vulnerable to whatever toxic or nutritional insult the disease creates. A rapidly progressing maculopathy, often described as a “bull’s-eye” pattern of damage centered on the macula, has been documented even in very young children.⁷ Nystagmus (involuntary eye movements) was noted in most patients in one series, and older patients showed retina-wide pigmentary changes beyond just the macula.⁸

Treatment with hydroxocobalamin can slow the progression of retinal disease and preserve better visual function, especially when started early. In sibling comparisons, younger siblings who received treatment from birth had less severe retinal findings and better functional vision than their older siblings who were treated later. But the retinopathy still progressed over time, suggesting that current therapy mitigates rather than prevents eye damage.⁹ This is one of the clearest areas where cobalamin C disease resists even the best available treatment.

Kidney Involvement

The kidneys can be hit in two ways. The more dramatic is atypical hemolytic uremic syndrome (aHUS), a condition where small blood vessels in the kidneys become damaged, red blood cells are destroyed, and kidney function rapidly declines. Cobalamin C disease is a recognized but rare cause of aHUS, driven by the toxic effects of elevated homocysteine and methylmalonic acid on the blood vessel lining.¹⁰ Cases of aHUS linked to cobalamin C disease have been reported primarily in infancy.¹¹ A more insidious form of kidney damage, glomerulonephritis, can also develop, particularly in late-onset patients. Because the kidney problems are secondary to the metabolic defect, the most effective treatment is correcting the underlying biochemistry rather than treating the kidneys in isolation.

Newborn Screening and Its Limits

Most developed countries include markers for cobalamin C disease in their newborn screening panels. The standard screen measures a compound called C3 (propionylcarnitine) in a dried blood spot taken from the baby’s heel. Elevated C3 raises a flag for several metabolic conditions, including cobalamin C disease. But C3 alone is not a perfect net. A screening study of over 300,000 newborns found that three infants diagnosed with the milder form of the disease had completely normal C3 levels on their second screen. Their disease was only caught because the screening center also measured methylmalonic acid directly, which was elevated in all three cases.¹²

This matters for families, because not all screening programs measure methylmalonic acid routinely. A normal newborn screen does not guarantee that a child is free of the condition, especially if milder or late-onset forms are involved. If a family has a known history of cobalamin C disease, targeted genetic testing of the MMACHC gene is far more reliable than relying on metabolic screening alone.

How the Diagnosis Is Confirmed

When cobalamin C disease is suspected, whether through a newborn screen flag, clinical symptoms, or family history, the diagnosis rests on a few key lab findings. Elevated methylmalonic acid and elevated total homocysteine in the blood or urine, combined with low methionine, form the hallmark biochemical pattern.¹³ That dual elevation distinguishes cobalamin C disease from conditions that raise only one of the two metabolites. Genetic sequencing of MMACHC then confirms the specific mutations and helps predict whether the disease is likely to follow an early- or late-onset course.

It is worth noting that eight different defects of intracellular cobalamin metabolism have been identified, and they are classified by complementation groups (cblA through cblJ, plus others). Cobalamin C is by far the most common of these. The others can cause isolated methylmalonic acidemia or isolated homocystinuria, but only the cblC group (along with the rarer cblD and cblF groups) causes both problems simultaneously.¹⁴

Treatment With Hydroxocobalamin

The backbone of treatment is intramuscular injections of hydroxocobalamin, a form of B12 that bypasses the broken MMACHC processing step more effectively than standard cyanocobalamin supplements. Hydroxocobalamin lowers methylmalonic acid and homocysteine levels in the blood and raises methionine levels.¹⁵ There are no universally agreed-upon dosing guidelines, and clinical practice varies widely. Some centers have found that escalating the dose over time, rather than maintaining a fixed low dose, produces better biochemical control.¹⁶

Betaine is often added as a second-line agent. It provides an alternative route for converting homocysteine back to methionine, helping to lower homocysteine levels further. Some patients also receive folinic acid, carnitine, or methionine supplements, though outcome data for these additional therapies remain limited.¹⁵

One important dietary nuance: unlike other forms of methylmalonic acidemia where restricting protein intake is standard, cobalamin C patients tend to have low methionine levels to begin with. Putting them on protein-restricted medical formulas designed for other methylmalonic acidemia patients can make the methionine deficiency worse. In one cohort, three-quarters of patients needed methionine supplementation starting in infancy to keep levels in the normal range.¹⁷

Does Intensifying the Dose Help Long-Term Outcomes

A persistent frustration in managing cobalamin C disease is that biochemical markers can look well controlled on paper while developmental and visual outcomes still deteriorate. This has led some clinicians to push hydroxocobalamin doses higher and start them earlier, a strategy sometimes called dose intensification. A small case series of five early-onset patients given dose-intensified hydroxocobalamin found that both visual and cognitive functions were better preserved when dose intensification was started early rather than late. None of the four patients with usable vision developed the classic bull’s-eye maculopathy that typically plagues early-onset patients, and only one patient had severe cognitive deficiency.¹⁸ These results are encouraging but come from only five patients, so they remain more a signal than proof.

Long-Term Prognosis

Even with newborn screening and prompt treatment, the long-term outlook for early-onset cobalamin C disease remains guarded. In a longitudinal cohort of patients identified through newborn screening, close to nine in ten had intellectual disability and three-quarters had retinopathy despite receiving standard therapy from infancy.¹⁷ A more recent study confirmed that despite early intervention, a substantial proportion of patients still developed developmental impairments or eye problems, and the severity appeared to correlate more with how sick the baby was at birth than with how well metabolic markers were controlled afterward.¹⁹

That last point is sobering and has real implications for counseling families: the initial metabolic storm in the newborn period may cause irreversible damage that no amount of subsequent biochemical control can undo. This is one reason researchers have turned their attention to prenatal treatment, with the aim of protecting the fetus before that damage occurs.

Late-onset patients generally fare better in terms of cognitive and overall function, but they are not without risk. Thromboembolic events like deep vein thrombosis or pulmonary embolism, progressive kidney disease, and neurological decline can all appear if the condition goes unrecognized or undertreated.

Prenatal Treatment

If a family already has a child with cobalamin C disease, future pregnancies can be monitored through genetic testing of the fetus. When a fetus is found to be affected, administering hydroxocobalamin injections to the mother during pregnancy has been tried. The B12 crosses the placenta and appears to provide some metabolic support to the developing baby.

A literature review of prenatally treated cases found that infants who received hydroxocobalamin before birth had milder phenotypes: none developed microcephaly, seizures, or severe multisystemic disease. Three of five infants carrying severe MMACHC mutations who received high-dose prenatal and postnatal hydroxocobalamin showed normal neurodevelopment and no maculopathy up to ages two to three, though the authors noted that small numbers and varying treatment protocols limit how broadly those results can be applied.²⁰ A separate case report reached a similar conclusion, suggesting that intrauterine treatment started as early as possible and continued throughout pregnancy may even prevent clinical symptoms altogether when combined with lifelong postnatal treatment.²¹

These findings are still preliminary. But they represent one of the few strategies that might change the trajectory for the most severely affected patients, by intervening before birth rather than scrambling to catch up afterward.

Gene Therapy Research

The ultimate fix for cobalamin C disease would be replacing or correcting the broken MMACHC gene. Researchers have tested this concept in a mouse model of the disease using adeno-associated viral (AAV) vectors, which are common gene therapy delivery vehicles. Mice that would normally die from the disease received a single dose of the gene therapy as newborns. The treated mice showed dramatically improved growth and survival, with the oldest living beyond nine months compared to untreated mice that die very early.²²

Gene therapy for cobalamin C disease in humans remains years away. The jump from mouse models to clinical trials is long, and AAV-based gene therapies carry their own risks, including immune reactions and the challenge of getting the therapeutic gene expressed in enough of the right tissues for a sustained period. Still, these animal results establish that correcting the genetic defect is biologically feasible, and they provide a foundation for future clinical development.

The MMACHC Protein Up Close

For those curious about what exactly is broken in this disease, structural biology has given a fairly detailed picture. The MMACHC protein works as a kind of molecular tool that strips chemical groups off of incoming B12 molecules, preparing them for conversion into the two active coenzymes. It uses a helper molecule called glutathione to carry out this stripping reaction. Crystal structures of the protein show that it forms a dimer, two copies clasping together, with a conserved loop from each copy reaching across to cap the B12 binding site on its partner.²³ One of the most common disease-causing mutations disrupts the pocket where glutathione binds, crippling the stripping reaction.

After MMACHC processes B12, it hands the product to a downstream partner protein called MMADHC, which directs the B12 toward either the adenosylcobalamin or methylcobalamin pathway depending on which enzyme needs it. Experiments show that the handoff between MMACHC and MMADHC only works properly after the stripping step is complete. When disease mutations impair stripping, the handoff fails as well, compounding the problem.²⁴ Understanding these molecular details has been essential for designing the gene therapy vectors that researchers are now testing, because the replacement gene must produce a protein capable of both the processing step and the partner handoff.